<DOC>
	<DOCNO>NCT00455494</DOCNO>
	<brief_summary>The purpose study test safety 2100 mg dose AQ-13 , new candidate antimalarial active drug-resistant P. falciparum infection , determine effect standard fatty meal absorption drug gut blood level .</brief_summary>
	<brief_title>Food-Effect Bioavailability Study AQ-13 , Candidate Antimalarial</brief_title>
	<detailed_description>This 2-stage , randomize crossover study 2100 mg AQ-13 dose healthy volunteer . Fourteen healthy volunteer randomize receive drug either empty stomach standard fatty meal continuous monitoring hospital . After washout period 8 week , volunteer admit hospital receive dose drug fatty meal empty stomach reverse – volunteer receive AQ-13 without fatty meal . Study Population : Healthy young men woman , 21-45 year age take chronic medication exception birth control pill invite participate food-effect bioavailability study Tulane-LSU General Clinical Research Center New Orleans . Exclusion criterion include pregnancy , breast feeding , abnormal liver kidney function test , anemia ( Hb &lt; 12 gm per dL ) , chronic medication birth control pill , abnormal baseline ECG Holter record . Randomization : Allocation code generate biostatistician block , use computer software , seal number , opaque envelope . Block size determine random know study personnel . The envelope contain randomization code hand-delivered study pharmacist keep Research Pharmacy , outside GCRC . Blinding : The investigator laboratory personnel perform laboratory test compare result , electrocardiograms Holter recording AQ-13 dos blind AQ-13 dos administer without fatty meal . However , volunteer nurse personnel GCRC know dos administer without fatty meal . Therefore , single-blinded study . Informed Consent : Informed consent obtain participant screening . According IRB guideline , informed consent form revise yearly interval whenever new information AQ-13 side effect become available . In-patient Procedures : On even admission , pregnancy test repeat CK measure drug administration follow morning . The drug administration protocol follow design outline FDA “ Guidance Industry ” food-effect bioavailability study ( 1-2 ) . The 2100 mg AQ-13 dose divide three dos 700 mg administer day morning empty stomach 240 ml water 10 hour fast empty stomach arm . For fatty meal arm , AQ-13 dose day 1 administer within 30 minute standard fatty meal , prepared describe FDA “ Guidance ” administer 240 ml water 10 hour fast . The fatty meal eat within 30 minute drug administer 30 minute start fatty meal . For arm , water allow 1 hour dose ; food allow 4 hour dose ( 2 ) . A small needle plastic tube blood thinner place participant ’ arm keep place paper tape draw blood sample . The participant monitor heart rhythm , use Holter monitor four day begin time first dose , electrocardiogram take 4 hour dose . The purpose cardiac monitoring test whether drug affect QTc interval heart rhythm . Three 24-hr urine sample collect start time first dose . Outpatient follow : After inpatient study General Clinical Research Center ( GCRC ) , participant ask return GCRC outpatient twice per week 4 week give ( 5 ml ) blood follow drug level blood . At 2 week follow visit , electrocardiogram , Holter recording , blood test hematology chemistry , visual exam do . At 4 week follow , additional ECG Holter record obtain . In second stage study , in-patient out-patient follow procedure first stage , except study drug administer empty stomach volunteer take drug fatty meal first stage vice versa . At least 8 week washout period must pass participate two stage study . References : 1. http : //www.fda.gov/oc/initiatives/hiv/hivguidance.html 2. http : //www.fda.gov/cder/guidance/5194fnl.pdf</detailed_description>
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Antimalarials</mesh_term>
	<criteria>Healthy volunteer 2145 year age take chronic medication birthcontrol pill Pregnancy , Breastfeeding , Chronic disease</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>April 2007</verification_date>
	<keyword>Drug-resistant malaria</keyword>
	<keyword>Bioavailability</keyword>
	<keyword>Food-effect study</keyword>
</DOC>